UBS Group
EVFM

UBS Group’s Evofem Biosciences, Inc. Common Stock EVFM Stock Holding History

UBS Group’s Portfolio EVFM Stock Details EVFM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-65
Closed – – 11834
2022
Q2 		$0 Sell
65
-78
-55% -$129 ﹤0.01% 11706
2022
Q1 		$1K Sell
143
-4,674
-97% -$29.4K ﹤0.01% 10140
2021
Q4 		$27K Buy
4,817
+1,722
+56% +$14.6K ﹤0.01% 7526
2021
Q3 		$34K Buy
3,095
+2,523
+441% +$31.7K ﹤0.01% 6659
2021
Q2 		$9K Sell
572
-1,036
-64% -$19.6K ﹤0.01% 8200
2021
Q1 		$43K Sell
1,608
-859
-35% -$39K ﹤0.01% 6710
2020
Q4 		$89K Buy
2,467
+1,023
+71% +$37K ﹤0.01% 5761
2020
Q3 		$51K Sell
1,444
-422
-23% -$18.3K ﹤0.01% 5641
2020
Q2 		$80K Buy
1,866
+1,293
+226% +$87.1K ﹤0.01% 5486
2020
Q1 		$46K Sell
573
-616
-52% -$49.3K ﹤0.01% 5905
2019
Q4 		$110K Buy
1,189
+445
+60% +$37.5K ﹤0.01% 5957
2019
Q3 		$57K Buy
744
+552
+288% +$42.4K ﹤0.01% 6133
2019
Q2 		$19K Buy
192
+170
+773% +$13.2K ﹤0.01% 6666
2019
Q1 		$1K Sell
22
-336
-94% -$18.2K ﹤0.01% 7603
2018
Q4 		$22K Buy
358
+336
+1,527% +$18.5K ﹤0.01% 6724
2018
Q3 		$1K Hold
22
– – ﹤0.01% 7881
2018
Q2 		$1K Hold
22
– – ﹤0.01% 7869
2018
Q1 		$2K Sell
22
-62
-74% -$7.96K ﹤0.01% 7580
2017
Q4 		$15K Sell
84
-175
-68% -$19.8K ﹤0.01% 6777
2017
Q3 		$11K Buy
259
+120
+86% +$4.63K ﹤0.01% 6853
2017
Q2 		$7K Buy
139
+117
+532% +$20.5K ﹤0.01% 7001
2017
Q1 		$3K Hold
22
– – ﹤0.01% 7219
2016
Q4 		$2K Sell
22
-48
-69% -$4.98K ﹤0.01% 7543
2016
Q3 		$7K Sell
70
-78
-53% -$7.15K ﹤0.01% 7006
2016
Q2 		$13K Buy
148
+126
+573% +$11.3K ﹤0.01% 6639
2016
Q1 		$1K Hold
22
– – ﹤0.01% 7484
2015
Q4 		$3K Buy
22
+21
+2,100% +$13.8K ﹤0.01% 7917
2015
Q3 		$1K Buy
+1
New +$1.07K ﹤0.01% 8258
2015
Q2 		– Sell
-18
Closed -$13K – 8970
2015
Q1 		$13K Buy
+18
New +$11.5K ﹤0.01% 7446

Other funds holding EVFM

CS
Clear Street New York $24.6B AUM 56.26% 1-Year Est. Return
AWM
Activest Wealth Management Aventure, Florida $518M AUM 44.34% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
WIM
Westside Investment Management Santa Monica, California $653M AUM 28.36% 1-Year Est. Return
LTI
Laffer Tengler Investments Nashville, Tennessee $782M AUM 33.6% 1-Year Est. Return

UBS Group's EVFM Position: Q3 2022 in Review

UBS Group sold out of Evofem Biosciences, Inc. Common Stock (EVFM) in Q3 2022, closing a stake of 65 shares.

UBS Group first reported a position in EVFM in Q1 2015 and held it in 29 quarters. The position peaked at $110K in Q4 2019. 8 funds tracked by Wall St. Rank hold EVFM as of Q3 2022.

  • UBS Group reported no remaining Evofem Biosciences, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • UBS Group sold 65 Evofem Biosciences, Inc. Common Stock shares in Q3 2022.
  • UBS Group first reported a position in Evofem Biosciences, Inc. Common Stock in Q1 2015 and held it in 29 quarters.
  • UBS Group's Evofem Biosciences, Inc. Common Stock position peaked at $110K in Q4 2019.
  • 8 funds tracked by Wall St. Rank held Evofem Biosciences, Inc. Common Stock as of Q3 2022.

Based on UBS Group's 13F filing for Q3 2022, filed 10 Nov 2022.